Evidence map›Paper›PMID 35013215›Full record

ArticleNature communications2022

Latency reversal plus natural killer cells diminish HIV reservoir in vivo.

Jocelyn T Kim, Tian-Hao Zhang, Camille Carmona, Bryanna Lee, Christopher S Seet, Matthew Kostelny, Nisarg Shah, Hongying Chen, Kylie Farrell, Mohamed S A Soliman and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. CD56bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 2 countries.

Jocelyn T Kim *Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA. jocelynkim@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-7040-5773
Tian-Hao Zhang *Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Camille CarmonaDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0001-7725-391X
Bryanna LeeDepartment of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Christopher S SeetDepartment of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-4821-1400
Matthew KostelnyDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Nisarg ShahDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Hongying ChenDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Kylie FarrellDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Mohamed S A SolimanDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0003-1892-4917
Melanie DimapasocDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0003-0328-315X
Michelle SinaniDepartment of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Kenia Yazmin Reyna BlancoDepartment of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA.
David BojorquezDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-4044-6635
Hong JiangDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.
Yuan ShiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-9993-0448
Yushen DuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.
Natalia L KomarovaDepartment of Mathematics, University of California, Irvine, Irvine, CA, 92697, USA.
Dominik WodarzDepartment of Population Health and Disease Prevention, Program in Public Health Susan and Henry Samueli College of Health Sciences, University of California, Irvine, Irvine, CA, 92697, USA.ORCID http://orcid.org/0000-0002-8017-3707
Paul A WenderDepartment of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, CA, 94305, USA.
Matthew D MarsdenDepartment of Microbiology and Molecular Genetics and Department of Medicine, Division of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, CA, 92697, USA.
Ren SunDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.
Jerome A ZackDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0001-5486-8495
University of California, Los Angeles · USUniversity of California, Irvine · USStanford University · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Viral Genetics CoreP01AI131294 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DU, YUSHENG · 2017 to 2021
$7.5M
SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENTR01CA031845 · NCI · STANFORD UNIVERSITY · PI PAUL Anthony WENDER · 1985 to 2026
$6.9M
Synthetic Studies Related to Cancer Research/TreatmentR37CA031845 · NCI · STANFORD UNIVERSITY · PI WENDER, PAUL ANTHONY · 2006 to 2015
$4.5M
In Vivo Gene Editing for HIV-1 CureR01AI145038 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y. · 2019 to 2023
$3.4M
HIV latency reversal through novel, potent PKC modulatorsR01AI124743 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WENDER, PAUL ANTHONY, ZACK, JEROME A. · 2016 to 2020
$3.3M
The Effect of Natural Killer Cell-Based Therapy on the HIV ReservoirK08AI155232 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, JOCELYN T · 2020 to 2024
$1.0M
Development of a novel platform for the discovery of antigen-specific TCRsK08CA235525 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEET, CHRISTOPHER · 2019 to 2023
$984k
HIV Latency Reversal Through Novel, Potent PKC ModulatorsR56AI124743 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WENDER, PAUL ANTHONY, ZACK, JEROME A. · 2021 to 2021
$798k
NCATS NIH HHS UL1 TR001881NCI NIH HHS K08 CA235525NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA031845NCI NIH HHS R37 CA031845NIAID NIH HHS K08 AI155232NIAID NIH HHS P01 AI131294NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI124743NIAID NIH HHS R01 AI145038NIAID NIH HHS R56 AI124743
6 · The paper itself

Abstract

HIV is difficult to eradicate due to the persistence of a long-lived reservoir of latently infected cells. Previous studies have shown that natural killer cells are important to inhibiting HIV infection, but it is unclear whether the administration of natural killer cells can reduce rebound viremia when anti-retroviral therapy is discontinued. Here we show the administration of allogeneic human peripheral blood natural killer cells delays viral rebound following interruption of anti-retroviral therapy in humanized mice infected with HIV-1. Utilizing genetically barcoded virus technology, we show these natural killer cells efficiently reduced viral clones rebounding from latency. Moreover, a kick and kill strategy comprised of the protein kinase C modulator and latency reversing agent SUW133 and allogeneic human peripheral blood natural killer cells during anti-retroviral therapy eliminated the viral reservoir in a subset of mice. Therefore, combinations utilizing latency reversal agents with targeted cellular killing agents may be an effective approach to eradicating the viral reservoir.

Indexed as

AnimalsAnti-HIV AgentsBone MarrowCD4-Positive T-LymphocytesCoculture TechniquesFemaleHIV-1HIV InfectionsHost-Pathogen InteractionsHumansKiller Cells, NaturalMaleMiceMice, TransgenicProtein Kinase CProtein Kinase InhibitorsAnti-HIV AgentsProtein Kinase CProtein Kinase Inhibitors

Identifiers

PMID35013215
PMCPMC8748509
OpenAlexW4205822842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.